FibroGen (NASDAQ:FGEN) Issues Earnings Results, Beats Expectations By $2.40 EPS

FibroGen (NASDAQ:FGEN) issued its earnings results on Monday. The biopharmaceutical company reported ($1.61) EPS for the quarter, beating the consensus estimate of ($4.01) by $2.40, Zacks reports.

FibroGen Stock Down 0.3%

FGEN traded down $0.03 during trading on Monday, reaching $11.00. 42,197 shares of the company were exchanged, compared to its average volume of 68,750. The company has a market cap of $44.48 million, a price-to-earnings ratio of -28.95 and a beta of 0.75. FibroGen has a 12-month low of $4.50 and a 12-month high of $21.94. The company’s 50-day moving average is $11.42 and its two-hundred day moving average is $9.02.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen raised FibroGen from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroGen in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $43.00 price target on shares of FibroGen in a report on Wednesday, September 24th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $43.00.

Institutional Trading of FibroGen

A hedge fund recently raised its stake in FibroGen stock. Vanguard Group Inc. grew its position in shares of FibroGen, Inc (NASDAQ:FGEN) by 3.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 184,244 shares of the biopharmaceutical company’s stock after acquiring an additional 6,204 shares during the period. Vanguard Group Inc. owned about 4.56% of FibroGen worth $2,257,000 at the end of the most recent quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.